Table 3.
Univariate analysis involving patients with follow-up data
| Characteristics | Training cohort (n = 64) | Test cohort (n = 20) | Total (n = 84) | |||
|---|---|---|---|---|---|---|
| Cutoff value | P | Cutoff value | P | Cutoff value | P | |
| Gender | M/F | 0.100 | M/F | 0.017 | M/F | 0.010 |
| Age | 60 | 0.184 | 60 | 0.041 | 60 | 0.742 |
| Serum LDH | 169* (0.092) | 0.263 | 223* (0.137) | 0.065 | 231.5 (0.019) | 0.000 |
| ECOG score | 0/1/2/3/4 | 0.057 | 0/1/2/3/4 | 0.023 | 0/1/2/3/4 | 0.005 |
| Ki67 | 60%* (0.767) | 0.548 | 80%* (0.665) | 0.870 | 70%* (0.970) | 0.809 |
| β2-microglobulin | 188* (0.076) | 0.387 | 454* (0.248) | 0.328 | 820 (0.040) | 0.001 |
| EBV DNA | +/− | 0.018 | +/− | 0.012 | +/− | 0.001 |
| Ann Arbor stage | I–II/III–IV | 0.000 | I–II/III–IV | 0.000 | I–II/III–IV | 0.000 |
| B symptoms | +/− | 0.300 | +/− | 0.441 | +/− | 0.193 |
| PSI with CDL | 1 | 0.000 | 1 | 0.018 | 1 | 0.000 |
| PSI with WSDL | 1 | 0.000 | 1 | 0.002 | 1 | 0.000 |
| SUVmax | 11.1* (0.382) | 0.876 | 15.05* (0.418) | 0.880 | 12.25* (0.218) | 0.871 |
| SUVmean | 6.35* (0.453) | 0.927 | 8.6* (0.298) | 0.312 | 6.875* (0.249) | 0.677 |
| MTV | 18.04 (0.002) | 0.000 | 15.695* (0.165) | 0.415 | 25.325 (0.001) | 0.000 |
| TLG | 94.738 (0.004) | 0.000 | 124.133* (0.316) | 0.415 | 109.952 (0.006) | 0.001 |
*Median value
Abbreviations: M, male; F, female; +, positive; −, negative; PFS, progression-free survival; PSI, prediction similarity index; WSDL, weakly supervised deep learning; CDL, conventional deep learning; LDH, lactate dehydrogenase; ECOG, Eastern Cooperative Oncology Group; EB virus, Epstein–Barr virus; SUV, standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis